{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:59:24Z","timestamp":1785560364539,"version":"3.56.0"},"reference-count":25,"publisher":"Editorial Committee of Annals of Thoracic and Cardiovascular Surgery","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ATCS","Ann Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5761\/atcs.oa.26-00107","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:12:01Z","timestamp":1785190321000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma"],"prefix":"10.5761","volume":"32","author":[{"given":"Ruihan","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-3732","authenticated-orcid":false,"given":"Shinji","family":"Mine","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomi","family":"Nasu","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Makuuchi","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Esophageal and Gastroenterological Surgery, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3757","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191\u2013203.","DOI":"10.1056\/NEJMoa2032125"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074\u201384.","DOI":"10.1056\/NEJMoa1112088"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450\u201361.","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455\u201365.","DOI":"10.1056\/NEJMoa1200694"},{"key":"6","unstructured":"6) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2026. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2026. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433. Accessed May 11, 2026."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus 2023; 20: 343\u201372.","DOI":"10.1007\/s10388-023-00993-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19: 68\u201374.","DOI":"10.1245\/s10434-011-2049-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus 2023; 20: 373\u201389.","DOI":"10.1007\/s10388-023-00994-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Koga N, Kimura Y, Yokomizo R, et al. Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: a single-center retrospective cohort study. Surg Today 2026; 56: 896\u2013905.","DOI":"10.1007\/s00595-025-03187-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yagi K, Toriumi T, Aikou S, et al. Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2021; 5: 436\u201345.","DOI":"10.1002\/ags3.12448"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hermanek P, Wittekind C. The pathologist and the residual tumor (R) classification. Pathol Res Pract 1994; 190: 115\u201323.","DOI":"10.1016\/S0344-0338(11)80700-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals. Dis Esophagus 2016; 29: 913\u20139.","DOI":"10.1111\/dote.12540"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals. Dis Esophagus 2016; 29: 897\u2013905.","DOI":"10.1111\/dote.12533"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205\u201313.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2. Esophagus 2019; 16: 25\u201343.","DOI":"10.1007\/s10388-018-0642-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 2024; 404: 55\u201366.","DOI":"10.2139\/ssrn.4663351"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Altorki N, Kent M, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236: 177\u201383.","DOI":"10.1097\/00000658-200208000-00005"},{"key":"19","unstructured":"19) Japan Registry of Clinical Trials. JCOG2206. jRCT identifier: jRCTs031230219. Ministry of Health, Labour and Welfare, Japan. Available from: https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs031230219. Accessed May 12, 2026."},{"key":"20","unstructured":"20) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute; 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed May 12, 2026."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714\u201368.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Mine S, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: part I. Esophagus 2024; 21: 179\u2013215.","DOI":"10.1007\/s10388-024-01054-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399\u2013424.","DOI":"10.1080\/00273171.2011.568786"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sugase T, Kanemura T, Takeoka T, et al. Short-term outcomes of adjuvant nivolumab after neoadjuvant chemotherapy in patients with resected esophageal squamous cell carcinoma. Anticancer Res 2024; 44: 185\u201393.","DOI":"10.21873\/anticanres.16801"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sugase T, Kanemura T, Matsuura N, et al. Survival impact of adjuvant nivolumab therapy for locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy with docetaxel plus 5-fluorouracil and cisplatin. Ann Surg Oncol 2025; 32: 5887\u201397.","DOI":"10.1245\/s10434-025-17332-7"}],"container-title":["Annals of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/32\/1\/32_oa.26-00107\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:42:08Z","timestamp":1785559328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/32\/1\/32_oa.26-00107\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5761\/atcs.oa.26-00107","relation":{},"ISSN":["1341-1098","2186-1005"],"issn-type":[{"value":"1341-1098","type":"print"},{"value":"2186-1005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"oa.26-00107"}}